Neonatal Hypertension Clinical Presentation

  • Author: Joseph Flynn, MD, MS; Chief Editor: Ted Rosenkrantz, MD   more...
 
Updated: Jan 3, 2012
 

History

In most newborns, hypertension is discovered on routine monitoring of vital signs. Other presentations of neonatal hypertension to be aware of in acutely ill infants include congestive heart failure (CHF) and cardiogenic shock, which are potentially life threatening. Fortunately, these consequences of hypertension gradually resolve with appropriate blood pressure (BP) reduction.

In the less acutely ill infant, feeding difficulties, unexplained tachypnea, apnea, lethargy, irritability, or seizures may constitute symptoms of unsuspected hypertension. In older infants who have been discharged from the nursery, unexplained irritability or failure to thrive may be the only manifestations of hypertension.

Focus the history on discovering any pertinent prenatal or postnatal exposures, as well as to the particulars of the infant's nursery course and any concurrent conditions. Review the procedures that the infant has undergone, especially umbilical catheter placement, and analyze the baby's current medication list. If the infant has been discharged from the nursery, the history should also cover symptoms related to possible underlying causes of hypertension (similar to the evaluation of hypertension in older children).

Next

Physical Examination

The physical examination should begin with 4-extremity blood pressure (BP) measurements in order to rule out aortic coarctation. Assess the general appearance of the infant and pay particular attention to the presence of dysmorphic features that may indicate an underlying genetic syndrome. Perform careful cardiac and abdominal examinations to rule out congestive heart failure (CHF) or renal anomalies. Examine the genitalia to rule out congenital adrenal hyperplasia (CAH). Neurologic examination may also be helpful, particularly in infants with intraventricular hemorrhage.

Normal blood pressure levels

BP in newborn infants is influenced by various factors, including birth weight, gestational age, and postconceptual age. Excellent data illustrating the importance of these factors were generated by Zubrow et al, who prospectively obtained serial BP measurements from nearly 700 infants admitted to several NICUs in a large metropolitan area over 3 months.[8] The investigators used these data to define the mean plus upper and lower 95% confidence limits for BP; their data clearly demonstrated increases in BP with increasing gestational age, birth weight, and postconceptual age.

A more recent study of hemodynamically stable premature and term infants admitted to the NICU showed that BPs on day 1 of life correlated with gestational age and birth weight.[9] However, another study of more than 400 term infants admitted to a postnatal ward in Australia showed no difference in BP on day 1 of life based on birth weight, length, or gestational age.[10] Thus, there appears to be physiologic differences in premature infants with respect to BP level that need to be taken into consideration when considering whether a particular BP value is normal or elevated.

Data from these studies have recently been summarized by Dionne et al,[11, 12] who generated a table of BP values that can be used in assessing if a neonate’s BP is normal or elevated (see Table 1 below). For older infants, the percentile curves generated by the 1987 Second Task Force on Blood Pressure Control in Childhood remain the most useful reference of normal BP values (see the image below).[13] These curves allow BP to be characterized as normal or elevated not only by age and sex but also by size, albeit to a somewhat limited extent.

Normal blood pressure percentile curves for older Normal blood pressure percentile curves for older infants. From the Second (1987) Task Force on Blood Pressure Control in Childhood; National Heart, Lung, and Blood Institute.

Defining hypertensive-level BP

Hypertension in adults is defined based upon occurrence of hard cardiovascular endpoints such as myocardial infarction, stroke, and death. Since these events occur rarely in the pediatric age group, the definition of hypertension in infants, children, and adolescents is a statistical one based on databases of BP readings obtained in healthy subjects. Thus, BP in the young is considered normal if less than the 90th percentile for age, sex, and height, and is considered hypertensive if it is greater than or equal to the 95th percentile.

For infants, the same definitions should probably be applied, although the available data on normal BP values in infancy is limited. The table summarized below is a useful reference for premature infants, while the Second Task Force curves (see image above) can be used for term and older infants. However, there are obvious shortcomings for both of these references, highlighting the need for additional studies of normal BP in infancy.

Table 1. Neonatal Blood Pressures and Potential Treatment Parameters. Adapted from Dionne et al.* (Open Table in a new window)

Postconceptual Age50th Percentile95th Percentile99th Percentile
44 weeks
SBP88105110
DBP506873
MAP638085
42 weeks
SBP8598102
DBP506570
MAP627681
40 weeks
SBP8095100
DBP506570
MAP607580
38 weeks
SBP779297
DBP506570
MAP597479
36 weeks
SBP728792
DBP506570
MAP577277
34 weeks
SBP708590
DBP405560
MAP506570
32 weeks
SBP688388
DBP405560
MAP496469
30 weeks
SBP658085
DBP405560
MAP486368
28 weeks
SBP607580
DBP385054
MAP455863
26 weeks
SBP557277
DBP305056
MAP385763

*Estimated values for blood pressures after age 2 weeks in infants from 26-44 weeks postconceptual age. The 95th and 99th percentile values serve as a reference to identify infants with persistent hypertension that may require treatment. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure.

Previous
 
 
Contributor Information and Disclosures
Author

Joseph Flynn, MD, MS  Director of Pediatric Hypertension Program, Division of Nephrology, Seattle Children's Hospital; Professor, Department of Pediatrics, University of Washington School of Medicine

Joseph Flynn, MD, MS is a member of the following medical societies: American Academy of Pediatrics, American Heart Association, American Society of Hypertension, American Society of Nephrology, American Society of Pediatric Nephrology, National Kidney Foundation, and Phi Beta Kappa

Disclosure: Novartis Pharmaceuticals Consulting fee Consulting; Pfizer, Inc Consulting fee Review panel membership

Chief Editor

Ted Rosenkrantz, MD  Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Arun K Pramanik, MD, MBBS Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center

Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

References
  1. Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. Am J Hypertens. Feb 1992;5(2):51-5. [Medline].

  2. Friedman AL, Hustead VA. Hypertension in babies following discharge from a neonatal intensive care unit. A 3-year follow-up. Pediatr Nephrol. Jan 1987;1(1):30-4. [Medline].

  3. Blowey DL, Duda PJ, Stokes P, Hall M. Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens. Sep 17 2011;[Medline].

  4. Neal WA, Reynolds JW, Jarvis CW, Williams HJ. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. Pediatrics. Jul 1972;50(1):6-13. [Medline].

  5. Abman SH, Warady BA, Lum GM, Koops BL. Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr. Jun 1984;104(6):928-31. [Medline].

  6. Alagappan A, Malloy MH. Systemic hypertension in very low-birth weight infants with bronchopulmonary dysplasia: incidence and risk factors. Am J Perinatol. Jan 1998;15(1):3-8. [Medline].

  7. Seliem WA, Falk MC, Shadbolt B, Kent AL. Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up. Pediatr Nephrol. Dec 2007;22(12):2081-7. [Medline].

  8. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol. Nov-Dec 1995;15(6):470-9. [Medline].

  9. Pejovic B, Peco-Antic A, Marinkovic-Eric J. Blood pressure in non-critically ill preterm and full-term neonates. Pediatr Nephrol. Feb 2007;22(2):249-57. [Medline].

  10. Kent AL, Kecskes Z, Shadbolt B, Falk MC. Normative blood pressure data in the early neonatal period. Pediatr Nephrol. Sep 2007;22(9):1335-41. [Medline].

  11. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. Jan 2012;27(1):17-32. [Medline].

  12. Dionne JM, Abitbol CL, Flynn JT. Erratum to: Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. Jan 2012;27(1):159-60. [Medline].

  13. Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics. Jan 1987;79(1):1-25. [Medline].

  14. Crossland DS, Furness JC, Abu-Harb M, et al. Variability of four limb blood pressure in normal neonates. Arch Dis Child Fetal Neonatal Ed. Jul 2004;89(4):F325-7. [Medline].

  15. Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiological parameters. Med Hypotheses. May 3 2010;[Medline].

Previous
Next
 
Normal blood pressure percentile curves for older infants. From the Second (1987) Task Force on Blood Pressure Control in Childhood; National Heart, Lung, and Blood Institute.
Table 1. Neonatal Blood Pressures and Potential Treatment Parameters. Adapted from Dionne et al.*
Postconceptual Age50th Percentile95th Percentile99th Percentile
44 weeks
SBP88105110
DBP506873
MAP638085
42 weeks
SBP8598102
DBP506570
MAP627681
40 weeks
SBP8095100
DBP506570
MAP607580
38 weeks
SBP779297
DBP506570
MAP597479
36 weeks
SBP728792
DBP506570
MAP577277
34 weeks
SBP708590
DBP405560
MAP506570
32 weeks
SBP688388
DBP405560
MAP496469
30 weeks
SBP658085
DBP405560
MAP486368
28 weeks
SBP607580
DBP385054
MAP455863
26 weeks
SBP557277
DBP305056
MAP385763
Table 2. Intravenous Drugs for Severe Hypertension in Neonates[11]
DrugClassIntravenous (IV) DosageComments
EsmololBeta blocker100-300 mcg/kg/min IV infusionVery short acting; constant IV infusion necessary
HydralazineVasodilator (arteriolar)0.15-0.6 mg/kg/dose IV bolus or 0.75-5mcg/kg/min IV constant infusionTachycardia is frequent adverse effect; must administer every 4 hours when administered as IV bolus
LabetalolAlpha blocker and beta blocker0.2-1 mg/kg/dose IV bolus or 0.25-3 mg/kg/h IV constant infusionHeart failure, bronchopulmonary dysplasia (BPD), relative contraindications
NicardipineCalcium channel blocker1-5 mcg/kg/min IV constant infusionMay cause reflex tachycardia
Sodium nitroprussideVasodilator (arteriolar and venous)0.5-10 mcg/kg/min IV constant infusionThiocyanate toxicity can occur with prolonged use (>72 h) or in renal failure; usual maintenance dose is below 2 mcg/kg/min; may use 10 mcg/kg/min for short duration (ie, < 10-15 min)
Table 3. Oral Antihypertensive Agents Useful for Treatment of Neonatal Hypertension[11]
DrugClassOral DosageComments
CaptoprilAngiotensin-converting enzyme (ACE) inhibitorUnder age 3 months: 0.01-0.5 mg/kg/dose 3 times daily; not to exceed 2 mg/kg/day



At or above age 3 months: 0.15-0.3 mg/kg/dose 3 times daily; not to exceed 6 mg/kg/day



Monitor serum creatinine and potassium levels
ClonidineCentral agonist0.05-0.1 mg/dose 2-3 times dailyAdverse effects include dry mouth and sedation; rebound hypertension with abrupt discontinuation
EnalaprilACE inhibitor0.08-0.6 mg/kg/day, given once or twice dailyMonitor serum creatinine and potassium levels
HydralazineVasodilator (arteriolar)0.25-1 mg/kg/dose 3-4 times daily; not to exceed 7.5 mg/kg/daySuspension stable up to 1 wk; tachycardia and fluid retention are common adverse effects; lupuslike syndrome may develop in slow acetylators
IsradipineCalcium channel blocker0.05-0.15 mg/kg/dose 4 times daily; not to exceed 0.8 mg/kg/d or 20 mg/daySuspension may be compounded; useful for both acute and chronic hypertension
AmlodipineCalcium channel blocker0.1-0.3 mg/kg/dose twice daily; not to exceed 0.6 mg/kg/d or 20 mg/dLess likely to cause sudden hypotension than isradipine
MinoxidilVasodilator (arteriolar)0.1-0.2 mg/kg/dose 2-3 times dailyMost potent oral vasodilator; excellent for refractory hypertension
PropranololBeta-blocker0.5-1 mg/kg/dose 3 times dailyMaximal dose depends on heart rate; may administer as much as 8-10 mg/kg/d if no bradycardia; avoid in infants with BPD
LabetalolAlpha and beta blocker1 mg/kg/dose 2-3 times daily, up to 12 mg/kg/dMonitor heart rate; avoid in infants with BPD
SpironolactoneAldosterone antagonist0.5-1.5 mg/kg/dose twice dailyPotassium-sparing diuretic; monitor electrolytes; several days necessary to observe maximum effectiveness
HydrochlorothiazideThiazide diuretic2-3 mg/kg/d orally every day or divided twice dailyMonitor electrolytes
ChlorothiazideThiazide diuretic5-15 mg/kg/dose twice dailyMonitor electrolytes
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.